» Articles » PMID: 25342642

Limited Family Structure and Triple-negative Breast Cancer (TNBC) Subtype As Predictors of BRCA Mutations in a Genetic Counseling Cohort of Early-onset Sporadic Breast Cancers

Abstract

Early-onset diagnosis is an eligibility criterion for BRCA1 and BRCA2 (BRCA) testing in sporadic breast cancer patients. Limited family structure has been proposed as a predictor of BRCA mutation status in this group of patients. An overwhelming amount of data supports a strong association between BRCA1 mutations and triple-negative breast cancer (TNBC). Here, we analyze the feasibility of using limited family structure and TNBC as predictors of BRCA mutation status in early-onset breast cancer patients attending genetic counseling units. We have conducted the study in a cohort of sporadic early-onset (≤35 years) breast cancer patients (N = 341) previously selected for BRCA genetic testing in Academic Hereditary Cancer Clinics from Spain. A retrospective review of medical records available at the time of risk assessment allowed us classifying patients according to family structure and TNBC. In addition, BRCAPRO score was calculated for all patients. Association between categorical variables was investigated using the Fisher's exact test. Binary Logistic Regression Analysis was used for multivariate analysis. Limited family structure (OR 3.61, p = 0.013) and TNBC (OR 3.14, p = 0.013) were independent predictors of BRCA mutation status. Mutation prevalence in the subgroup of patients with at least one positive predictor was 14%, whereas it dropped to 3% in non-TNBCs with adequate family history (OR 5.31, 95% CI 1.38-23.89, p = 0.006). BRCAPRO correctly discerned between limited and adequate family structures. Limited family structure and TNBC are feasible predictors of BRCA mutation status in sporadic early-onset (≤35 years) breast cancer patients attending genetic counseling units. The low prevalence of mutations observed in non-TNBCs with adequate family structure suggests that this subgroup of patients might be excluded from genetic testing.

Citing Articles

mutation spectrum in Chinese early-onset breast cancer.

Shen M, Yang L, Lei T, Xiao L, Li L, Zhang P Transl Cancer Res. 2022; 8(2):483-490.

PMID: 35116780 PMC: 8798914. DOI: 10.21037/tcr.2019.03.02.


Breast MRI texture analysis for prediction of BRCA-associated genetic risk.

Vasileiou G, Costa M, Long C, Wetzler I, Hoyer J, Kraus C BMC Med Imaging. 2020; 20(1):86.

PMID: 32727387 PMC: 7388478. DOI: 10.1186/s12880-020-00483-2.


Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.

Garmpis N, Damaskos C, Garmpi A, Nikolettos K, Dimitroulis D, Diamantis E In Vivo. 2020; 34(4):1715-1727.

PMID: 32606140 PMC: 7439891. DOI: 10.21873/invivo.11965.


A systematic review of the international prevalence of mutation in breast cancer.

Armstrong N, Ryder S, Forbes C, Ross J, Quek R Clin Epidemiol. 2019; 11:543-561.

PMID: 31372057 PMC: 6628947. DOI: 10.2147/CLEP.S206949.


Association Between Status and Triple-Negative Breast Cancer: A Meta-Analysis.

Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S Front Pharmacol. 2018; 9:909.

PMID: 30186165 PMC: 6111442. DOI: 10.3389/fphar.2018.00909.